Immunotech Biopharm Ltd Ordinary Shares 06978
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- HKD 3.37
- Day Range
- HKD 3.22–3.58
- 52-Week Range
- HKD 3.02–5.00
- Bid/Ask
- HKD 3.19 / HKD 3.31
- Market Cap
- HKD 1.70 Bil
- Volume/Avg
- 22,000 / 43,165
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company in China. The company is focused on the research, development, and commercialization of T-cell immunotherapy. Its product EAL is a multi-target cellular immunotherapy product for the treatment of various types of cancer. Its product pipeline features classes of cellular immunotherapy products, including both non-genetically modified and genetically modified products, as well as both multi-target and single-target products. Its other products include the CAR-T cell series and the TCR-T cell series.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 210
- Website
- http://www.eaal.net
Comparables
Valuation
|
Metric
|
06978
|
09966
|
02105
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.90 | 2.44 | 2.72 |
Price/Sales | — | 18.52 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
06978
|
09966
|
02105
|
|---|---|---|---|
Quick Ratio | 1.77 | 6.35 | 9.91 |
Current Ratio | 1.81 | 6.59 | 9.98 |
Interest Coverage | −39.58 | −25.61 | −447.63 |
Quick Ratio
06978
09966
02105
Profitability
|
Metric
|
06978
|
09966
|
02105
|
|---|---|---|---|
Return on Assets (Normalized) | −26.86% | −11.93% | −48.47% |
Return on Equity (Normalized) | −49.11% | −16.61% | — |
Return on Invested Capital (Normalized) | −33.40% | −15.27% | — |
Return on Assets
06978
09966
02105
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Rycwwkjcv | Srjcx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rbpwqgyh | Wlsltwc | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rjhmnnck | Hrphp | $97.8 Bil | |
MRNA
| Moderna Inc | Bjvnfdwv | Rhgp | $41.3 Bil | |
ARGX
| argenx SE ADR | Jzfpyblny | Wcq | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Mbqggfr | Xmdy | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Wqpmxnl | Vlzzgw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xjhjclxz | Wfcsp | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Vdznlpzx | Wvtqlw | $12.5 Bil | |
INCY
| Incyte Corp | Ykdtsvwx | Cdsqyc | $11.6 Bil |